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Abstract
Background: The human leukocyte antigen alleles have been implicated as probable genetic markers in predicting the
susceptibility and/or protection to severe manifestations of dengue virus (DENV) infection. In this present study, we aimed
to investigate for the first time, the genotype variants of HLA Class 1(-A and -B) of DENV infected patients against healthy
individuals in Malaysia.
Methodology/Principal Findings: This study was carried out with 92 dengue disease patients and 95 healthy controls from
three different ethnic groups (Malay, Chinese and Indian) in Malaysia. All patients with clinical and laboratory confirmation
of DENV infection were typed for the HLA-A and B loci, using polymerase chain reaction-sequence specific primer
techniques. In our total population, a significant increase for HLA-B*53 (P=0.042, Pc=1.008) allele and a significant decrease
for A*03 (P=0.015, Pc=0.18, OR=5.23, 95% CI=1.19–23.02) and B*18 (P=0.017, Pc=0.408) alleles were noted in DHF
patients as compared to healthy donors. We also observed that in the Malay DHF patients, allele B*13 (P=0.049, Pc=1.176,
OR=0.18, 95% CI=0.03–0.90) was present at a significantly higher frequency in this population while allele HLA-B*18
(P=0.024, Pc=0.576) was seen to be negatively associated with DHF.
Conclusions/Significance: These are the first findings on genetic polymorphisms in our population and we conclude that:
(1) In our total population, HLA-B*53 probably involve in disease susceptibility, while the HLA-A*03 and HLA-B*18 may
confer protection from progression to severe disease; (2) In the Malay population, HLA-B*13 and B*18 are probably
associated in disease susceptibility and protection, respectively. These results could furnish as a valuable predictive tool to
identify ethnically different individuals at risk and/or protection from severe forms of DENV infection and would provide
valuable informations for the design of future dengue vaccine.
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Introduction
Malaysia consists of two geographical regions divided by the
South China Sea (latitude 2u309 N, longitude 112u309 E), with a
population of 27.5 million people, consisting of multi-ethnic
groups (Malay 53.3%, Chinese 26.0%, Indigenous 11.8%, Indian
7.7%, others 1.2%) [1]. History has revealed that Malaysia’s
geographical position places it between the great civilizations of
Europe and the Middle East to the West and China and Japan to
the East. This has made Malaysia a natural meeting place of trade
routes and ultimately formed a multi-racial and multi-cultural
nation [2].
The existence of varied human populations in Malaysia implies
diverse genetic diversity, such as in the human leukocyte antigen
(HLA) alleles. HLA is encoded by the major histocompatibility
complex (MHC) and is located on the chromosome 6 in humans
[3]. Both class I and II molecules are involved in displaying
peptide antigen to host T lymphocytes in order to activate immune
response [4]. However, the interaction between antigenic epitopes
and the host immune system varies with the HLA allele involved
[5]. This information on HLA alleles would probably be useful in
identifying appropriate epitopes for inclusion in molecular
vaccines and in determining the possible efficacy of these vaccines
in a particular population [6].
Dengue viruses (DENVs) belong to the genus flavivirus, family
Flaviviridae and are subgrouped into four serotypes: (DENV-1 to
DENV-4) [7,8]. This virus causes dengue fever (DF), dengue
hemorrhagic fever (DHF) and dengue shock syndrome (DSS)
which are identified as the most extensive vector-borne viral
disease in humans. The virus is prevalent in tropical and sub-
tropical regions around the world, predominantly in urban and
semi-urban areas. Dengue fever has been endemic in Malaysia
since 1901 [9] and reached epidemic proportions in 1973 [10–13].
In 1982, Malaysia experienced a major dengue/dengue hemor-
rhagic fever outbreak, which has affected all states in Peninsular
and East Malaysia [14]. Since than, dengue has became a major
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states in Malaysia.
Almost 50% of the infections are recognized to be clinically
silent infections [15]. In about 5–30% of the cases, the disease can
be severe and complicated, with the symptoms of thrombocyto-
penia, plasma leakage, bleeding, and hypovolemic shock com-
monly referred to as DHF and DSS [16,17]. The phenomenon of
Antibody Dependent Enhancement (ADE) theory postulates that
the infection with one dengue serotype during primary infection
confers future protective immunity against that particular serotype
but not with other serotypes during a secondary infection [18].
In addition to the ADE hypothesis, viral virulence and
interferon (IFN) mediated immunopathogenesis are insufficient
to explain clinical manifestations which have been implicated in
the pathogenesis of DHF. Others have suggested that, host genetic
factors, such as HLA alleles, play an important role in
susceptibility or protection in dengue viral infections [19,20].
Limited work has been established on the role of classical HLA-A
and -B alleles in determining resistance, susceptibility, or the
severity of acute viral infections in diverse populations worldwide.
Previous studies have suggested that polymorphisms especially in
this class I region gene were found to be associated with DHF
disease both in susceptibility and protection. However, these
associations also might vary by ethnic and geographical distribu-
tion. Study on DENV infected Thai and Cuban patients suggested
that the classical class I serotype HLA-A2 was found to be in
higher frequency in Thai DHF patients but this association was
not seen in the Cuban study [19,20]. More recently, two different
molecular analysis of HLA class I allele profiles in Vietnamese and
Cuban patients have provided evidence for association of various
HLA class 1 loci with susceptibility to DHF [21,22].
To our knowledge, the frequencies of HLA class 1 alleles in
Malaysian population infected with DENV have not been
documented previously. Thus, this study aimed to analyze the
frequency, variation and specific polymorphism in HLA class I, A
and B regions in DENV infected patients in the three ethnic
groups (Malay, Chinese and Indian) in Malaysia. This would be an
effort to determine the mechanisms of certain alleles that could be
a contributing factor in susceptibility and/or protection against
DENV infection in our population.
Materials and Methods
Study population
The study was carried out from January 2005 to June 2008.
Blood samples were obtained from 41 (14 Malay, 14 Chinese and
13 Indian) clinically diagnosed adult patients with DF and 51 (19
Malay, 16 Chinese and 16 Indian) adult patients with DHF who
were admitted to the University Malaya Medical Centre
(UMMC) Kuala Lumpur, Malaysia. Three ml of blood was
collected from each patient each in EDTA containing tube and in
a plain tube. Patients with DF and DHF were classified according
to World Health Organization (WHO) criteria (WHO, 2009).
Age, gender, race and medical history were recorded for each
patient. Clinical information including ascites, pleural effusion
and circulatory disturbance as a result of plasma leakage were
collected to enable disease classification. Platelet counts and
hematocrit values were recorded serially during hospitalization.
As for the background population for this genetic study, five ml of
blood was retrieved in an EDTA containing tube and also in a
plain tube from 95 unrelated healthy donors (32 Malays, 32
Chinese and 31 Indians), with no history of DENV infection.
Only patients and donors with both parents were from the same
race were included in this study.
Ethics Statement
Written informed consent was obtained from the patients and
donors. Ethical clearance has been approved by the Scientific and
Ethical Committee at the University Malaya Medical Centre
(UMMC) (Ethics Committee/IRB Reference No: 321.4).
Dengue virus PCR and serology
Dengue virus RNA was extracted from serum samples using the
QIAamp
R Viral RNA mini kit (Qiagen). RNA was reverse
transcribed and a one step real-time RT-PCR assay was
performed using SYBR-Green technology for detection of four
different DENV serotypes [23]. All samples were further
confirmed for DENV infection serologically using an in-house
capture IgM Enzyme-Linked Immunosorbent Assay (ELISA) [24].
The primary and secondary DENV infection were defined based
on the IgG antibody titers determined by a haemagglutination
inhibition (HI) test in paired acute and convalescent sera [25].
Human DNA extraction
Human DNA was extracted from whole blood using the
AccuPrep
R Genomic DNA extraction kit (Bioneer, USA) following
the manufacturer’s instructions. Briefly, 200ml of whole blood were
added to each tube containing 20 ml Proteinase K. Following that,
200 ml of binding buffer was added into this mixture and
resuspended to achieve maximum lysis efficiency and incubated
at 60uC for 10 minutes. After the addition of 100ml isopropanol,
the lysate was transferred to the upper reservoir of the binding
column tube and centrifuged at 8000 rpm for 1 minute. The
reservoir was then transferred to new tube and washed twice with
washing buffer 1 and 2 and centrifuged at 8000 rpm for 1 minute.
After final centrifugation at 12,000 rpm for 1 minute, DNA was
eluted in 200 ml of elution buffer by centrifugation at 8000 rpm for
1 min in a new tube and frozen in 220uC till use.
HLA typing
HLA types of all the study subjects were determined using a
sequence-specific primers (SSP) for HLA-A (Lot No: R53, X92,
26F) Combi Tray (24 tubes) and HLA-B (Lot No: V30, X82, Y52,
76E) Combi Tray (48 tubes) (Olerup SSP
TM, Saltsjobaden,
Sweden) according to the manufacturer’s instructions. The
HLA-A*24 subtyping was performed using the SSP for HLA-
A*24 high resolution (Lot No: X96, 63E) Combi Tray (48 and 76
tubes) (Olerup SSP
TM, Saltsjobaden, Sweden). Olerup SSP HL-A,
HLA-B and HLA-A*24, PCR master mix complete with
nucleotides, buffer, glycerol and cresol red were used for the
PCR reaction. The DFS-taq DNA polymerase (Bioron GmbH)
was added separately to the reaction tube. PCR amplification was
carried out in a 96 well thermal cycler with a heated lid. The
presence and absence of specific PCR products were documented
using the UV transilluminator. Interpretations of the typing were
done with the lot-specific interpretation and specificity tables. The
occurrences of specific HLA alleles observed in the control groups
were similar to previous report by others [26–28].
Statistical analysis
The analysis was performed to examine the association between
allele prevalence and dengue infection. For each HLA allele, the
proportion of DENV infected patients and control subjects with
the allele were compared, using allele frequency (AF) values. The
degree of association between HLA alleles and disease state was
expressed as the odds ratio (OR), which is obtained from standard
contingency table analysis by Haldane’s modification of Woolf’s
method. Groups with higher OR value are suggestive of increased
HLA and Dengue
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chi-square analysis of 262 tables with values,0.05 as being
significant. Fisher’s exact test is a statistical significance test used in
the analysis of categorical data where sample sizes are small. The
test is used to examine the significance of association between two
variables and was used when any value in the cell was ,5. P-
values were further subjected to correction according to the
Bonferroni’s inequality method (corrected P, Pc) by multiplying the
P-values with the number of alleles tested for each locus. The Pc
value effectively raise the standard of proof needed when a wide
range of hypotheses are looked at simultaneously. The SPSS
software package SPSS, version 14 (SPSS, Inc., Chicago, Ill.), was
used for all analysis.
Results
Characteristics of study population
This study was carried out at the UMMC, Kuala Lumpur,
Malaysia. We selected 92 patients (41 DF and 51 DHF) with
confirmed DENV infection and investigated their HLA alleles
associations with the dengue disease. The patients’ mean age was
30.18 years (range, 13 to 63), and they were selected from the
three ethnic groups in Malaysia. The mean duration of illness was
5 days (range, 4 to 9 days). Dengue IgM positive was detected in
the serum samples in 85 patients. The HI titre of ,1280 indicates
patients with primary infection while those with titres .2560
indicated a secondary infection. For the period of hospital
admission, the average maximum hematocrit recorded was 43%
(range, 29 to 54%) in both DF and DHF patients. The mean nadir




6/ml) in DF and 47.81 (range, 8610
6 to 249610
6/ml)
in DHF patients. In our healthy adult individuals, dengue IgM and
HI titres were ,10 indicating there were no asymptomatic DENV
infection in these individuals.
Frequencies of HLA class 1 A and B in Malaysian
individuals with dengue viral infections and in control
subjects
Table 1 shows the frequencies of the HLA class 1 specificities in
our dengue case patients. Among the 21 HLA-A alleles studied, 4
alleles were determined to be at frequencies of more than 5%
among the Malay and Chinese patients (A*02, A*11, A*24,
and A*33). These four predominant HLA-A alleles in Malay
and Chinese dengue patients coincide with the ethnically and
geographically matched control groups in this study. There was
however one allele (A*03) that was shown to be present at higher
levels in the healthy control group (Table 2).
Table 1. HLA-A, and -B allele frequencies in Malaysian individuals with dengue virus infection (dengue fever and dengue
hemorrhagic fever).
Total Patients Malay Chinese Indian Total Patients Malay Chinese Indian
HLA AF (%) AF (%) AF (%) AF (%) HLA AF (%) AF (%) AF (%) AF (%)
A01 5.43 4.55 0 12.07 B07 5.98 6.06 1.67 10.34
A02 20.65 19.70 26.67 15.52 B13 9.78 12.12 6.67 10.34
A03 3.26 1.52 0 8.62 B14 0.54 0 1.67 0
A11 25.54 16.67 41.67 18.97 B15 14.67 22.73 13.33 6.9
A24 25.54 34.85 18.33 22.41 B18 0.54 0 1.67 0
A26 1.63 1.52 0 3.45 B27 1.09 0 3.33 0
A30 2.72 3.03 0 5.17 B35 7.61 4.55 5 13.79
A31 2.17 0 1.67 5.17 B37 3.80 3.03 3.33 5.17
A32 0.54 0 1.67 0 B38 5.43 12.12 3.33 0
A33 7.61 12.12 10 0 B39 0.54 0 1.67 0
A34 1.63 4.55 0 0 B40 12.5 7.58 16.67 13.79
A68 3.26 1.52 0 8.62 B44 1.63 3.03 0 1.72
B46 5.43 4.55 11.67 0
B47 0.54 1.52 0 0
B48 2.72 4.55 3.33 0
B51 6.52 4.55 3.33 12.07
B52 5.43 4.55 1.67 10.34
B53 1.63 1.52 3.33 0
B54 2.17 1.52 5 0
B55 1.09 1.52 1.67 0
B56 2.17 0 3.33 3.45
B57 3.80 1.52 0 10.34
B58 3.26 3.03 6.67 0
B78 1.09 0 1.67 1.72
HLA=human leukocyte antigen; AF=allele frequency (as percentage).
Bold alleles are the predominant alleles present at frequencies more than 5%.
doi:10.1371/journal.pone.0013029.t001
HLA and Dengue
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A*24, A*30, A*31 and A*68) were noted to be at frequencies of
more than 5% (Table 1) of which six were also present at more
than 5% (A*01, A*02, A*03, A*11, A*24 and A*68) in the control
group. The other two alleles (A*30 and A*31) were present at
lower levels (,5%) in the healthy control group (Table 2).
Taking all dengue patients irrespective of race, 5 alleles were
determined to be at frequencies of more than 5% [A*11 (25.54%),
A*24 (25.54%), A*02 (20.65%), A*33 (7.61%) and A*01 (5.43%)]
(Table 1). These five predominant HLA-A alleles in dengue case
patients are also present in matched control groups in this study. There
was however one allele (HLA-A*03) that was shown to be present at
significantly higher levels in the healthy individuals (Table 2).
Of the 36 HLA-B alleles studied, B*07, B*13, B*15, B*38 and
B*40 were the most common alleles found at frequencies greater
than 5% in Malay dengue patients (Table 1). Three predominant
alleles (B*15, B*38 and B*40) were matched with healthy
individuals. There were however two alleles (B*07 and B*13) that
were shown to be present at lower levels (,5%) in the Malay
healthy individuals. Consequently, we also noted three other
alleles (B*18, B*35 and B*58) were present more than 5% of allele
frequencies in control group in this population (Table 2).
Among the Chinese patients, B*13, B*15, B*35, B*40, B*46,
B*54 and B*58 were the most predominant alleles (Table 1). These
alleles were also common in the Chinese control group with the
exception for HLA-B*54. The allele HLA-B*38 was noted to be
present at more than 5% in healthy group but not in this group of
patients (Table 2).
For the Indian patients, the B*07, B*13, B*15, B*35, B*37, B*40,
B*51, B*52 and B*57 were the most predominant alleles (Table 1).
These alleles were also present at frequencies of more than 5% except
for HLA-B*37 in the Indian healthy group (Table 2). Overall in all the
patients, B*15(14.67%), B*40(12.50%), B*13(9.78%), B*35(7.61%),
B*51(6.52%), B*07(5.98%), B*38(5.43%), B*46(5.43%) and B*52
(5.43%) were the most common alleles found at higher levels in dengue
patients and this coincides with the control groups, with the exception
of B*38, B*46 and B*52, which found to be lower (,5%) in controls.
It was noted however that HLA-B*18 and B*58 alleles were present
at higher levels in healthy individuals. These predominant alleles
have also been reported by others in Malaysia [26–28].
In this study, we then further analyzed all the alleles without
excluding the rare alleles as these alleles may also contribute to the
disease associations.
Positive associations of HLA-A with DF and DHF
Table 3 and 4 show the positive associations of both HLA-A
and HLA-B alleles in the different races for both DF and DHF
patients. As seen HLA-A*30 allele frequency was increased 2.3
Table 2. HLA-A, and -B allele frequencies in control subjects (ethnically and geographically matched, healthy Malaysian
individuals).
Total Controls Malay Chinese Indian Total Controls Malay Chinese Indian
HLA AF (%) AF (%) AF (%) AF (%) HLA AF (%) AF (%) AF (%) AF (%)
A01 6.84 3.13 3.13 14.52 B07 5.26 4.69 1.56 9.68
A02 20.00 14.06 26.56 19.35 B08 0.53 0 0 1.61
A03 9.47 9.38 6.25 12.90 B13 6.32 3.13 9.38 6.45
A11 24.21 25 34.38 12.90 B14 0.53 0 1.56 0
A24 21.58 34.38 9.38 20.97 B15 12.63 15.63 7.81 14.52
A26 1.05 0 0 3.23 B18 5.26 12.5 1.56 1.61
A29 0.53 0 0 1.61 B27 1.58 1.56 1.56 1.61
A30 0.53 1.56 0 0 B35 12.11 15.63 7.81 12.9
A31 1.58 0 3.13 1.61 B37 2.63 3.13 0 4.84
A32 0.53 0 0 1.61 B38 4.74 6.25 7.81 0
A33 10.53 9.38 17.19 4.84 B39 2.63 3.13 3.13 1.61
A34 1.05 3.13 0 0 B40 12.11 6.25 17.19 12.9
A68 2.11 0 0 6.45 B42 0.53 1.56 0 0
B44 2.63 3.13 3.13 1.61
B46 4.74 3.13 10.94 0
B47 0.53 0 1.56 0
B48 0.53 1.56 0 0
B51 5.79 4.69 4.69 8.06
B52 4.21 4.69 0 8.06
B54 1.05 0 3.13 0
B55 1.58 1.56 1.56 1.61
B56 1.58 1.56 0 3.23
B57 2.63 0 1.56 6.45
B58 7.89 6.25 14.06 3.23
HLA=human leukocyte antigen; AF=allele frequency (as percentage).
Bold alleles are the predominant alleles present at frequencies more than 5%.
doi:10.1371/journal.pone.0013029.t002
HLA and Dengue
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Malay DF patients while HLA-A*26 and HLA-A*68 alleles were
increased 2.6 fold in Malay DHF patients (P=0.373, Table 4) as
compared to matched controls. For the Chinese group, no
associations (.2 fold increase in AF) of HLA-A alleles were
observed between the DF patients and controls. However, HLA-
A*24 increased 2.0 fold (P=0.206, 0R=0.45, 95% CI=0.13–
1.52) and HLA-A*32 increased 3.1 fold (P=0.333) in DHF
patients as compared to healthy individuals in this population
(Table 4). In the Indian patients, increased frequencies of HLA-
A*68 (2.4 fold rise, P=0.658, 0R=0.38, 95% CI=0.09–1.65)
were noted in DF patients as compared to controls (Table 3) while
for DHF Indian patients, HLA-A*30 (6.3 fold rise, P=0.113) and
A*31 (3.9 fold rise, P=0.266, 0R=0.25, 95% CI=0.02–2.82)
alleles were observed to be increased in this population compared
to healthy controls (Table 4).
Taking the total dengue cases in all the three ethnic groups, the
HLA-A*68 allele was increased in frequency among DF patients
only when compared to control group in our population (2.3 fold
rise, P=0.248, 0R=0.42, 95% CI=0.10–1.72). The HLA-A*30
allele on the other hand was noted to be present at increased
frequencies in both DF (4.6 fold rise, P=0.217, 0R=0.21, 95%
CI=0.02–2.37) and DHF (5.5 fold rise, P=0.124, 0R=0.18, 95%
CI=0.02–1.70) patients in the population.
Positive associations of HLA-B with DF and DHF
As depicted in Table 3 and 4, positive associations were also
seen for HLA-B alleles in DENV infected patients. In the Malay
patient group a 2.3 fold rise in HLA-B*40 (P=0.24, 0R=0.4,
95% CI=0.09–1.73), B*37and B*46 (P=0.582, 0R=0.419, 95%
CI=0.06–3.14) alleles were detected in DF patients compared to
controls. For the DHF group HLA-B*38 allele increased 2.1 fold
(P=0.287, 0R=0.44, 95% CI=0.11–1.75) and B*53 and B*54
alleles increased 2.6 fold (P=0.373) as compared to healthy
controls in this population. Taking both DF and DHF patients
among the Malays increased frequencies of HLA-B*13 (2.3 fold
rise, P=0.582, 0R=0.42, 95% CI=0.06–3.14 in DF; 5.1 fold
rise, P=0.049, Pc=1.176; 0R=0.18, 95% CI=0.03–0.90 in
DHF) and B*48 (2.3 fold rise, P=0.518, 0R=0.43, 95%
CI=0.03–7.11 in DF; 3.4 fold rise, P=0.554, 0R=0.29, 95%
CI=0.03–3.26 in DHF) alleles were noted.
In the Chinese DF patients, HLA-B*15 increased 2.7 fold
(P=0.084, 0R=0.31, 95% CI=0.09–1.12), B*18 increased 2.3
fold (P=0.518, 0R=0.43, 95% CI=0.03–7.11) and B*78
increased 3.6 fold (P=0.304) while in the Chinese DHF patients
rising frequencies of HLA-B*07, B*14 (2.0 fold rise, P=1,
0R=0.49, 95% CI=0.030–8.13), B*27 (4.0 fold rise, P=0.257,
0R=0.24, 95% CI=0.02–2.73), B*37, B*53, B*56 (6.3 fold rise,
P=0.109) and B*52 (3.1 fold rise, P=0.333) alleles were noted as
compared to healthy individuals. In addition, HLA-B*48 (3.6 fold
rise, P=0.304 in DF; 3.1 fold rise, P=0.333 in DHF) allele was
increased in both patient groups.
Among the Indian DF population, HLA-B*51 increased 2.9 fold
(P=0.076, 0R=0.29, 95% CI=0.08–1.06), B*56 increased 2.4
fold (P=0.578, 0R=0.40, 95% CI=0.05–3.00) and B*78
increased 3.9 fold (P=0.295) as compared to healthy controls.
However, there were no associations of HLA-B alleles were noted
in between the DHF patients and controls in this population.
Taking the total dengue cases in all the three ethnic groups, we
noticed increased frequencies of HLA-B* 78 (2.4 fold rise,
P=0.09) allele in DF patients when compared to healthy controls
while in the DHF group HLA-B*53 increased 2.9 fold (P=0.042,
Pc=1.008) as compared to healthy individuals. We also observed
increases in the HLA-B*48 allele in both DF (4.6 fold rise,
P=0.217, 0R=0.21, 95% CI=0.02–2.37) and DHF (5.5 fold rise,
P=0.124, 0R=0.18, 95% CI=0.02–1.7) patients.
Negative HLA-A and B associations with DF and DHF
Table 5 and 6 show the negative associations of HLA-A and B
in the various ethnic groups of dengue disease patients. Within the
Malay and Chinese DF patient group there were no negative
associations of HLA-A alleles were observed (Table 5). However in
the Indian DF patients a 2.5 fold decrease was noted with HLA-
A*02 allele (P=0.216, 0R=2.89, 95% CI=0.60–13.9). For the
DHF group however, the HLA-A03 allele frequency was observed
to decrease in the three different racial groups (Malay: 9.4 fold
decrease, P=0.082; Chinese: 6.3 fold decrease, P=0.298; Indian:
2.1 fold decrease, P=0.486). Taking DHF patients in total this
trend was also observed (4.8 fold decrease, P=0.015, 0R=5.23,
95% CI=1.19–23.02). Two other alleles (HLA-A*01 and A*31:
3.1 fold decrease, P=0.551) were found to be absent in the
Chinese DHF patient group, while in the Indian DHF patient
group HLA-A*33 (4.8 fold decrease, P=0.549) and HLA-A*68
alleles were noted to be present at decreased levels (2.1 fold
decrease, P=0.658, 0R=2.14, 95% CI=0.23–19.97).
Table 3. Positive associations of HLA alleles in DF patients in
different races.
Alleles AF% AF% Fold P-value OR 95% CI
(PT) (CTRL)
Malay (n=14)
A*30 3.57 1.56 2.3 0.518 0.43 0.03–7.11
B*13 7.14 3.13 2.3 0.582 0.42 0.06–3.14
B*37 7.14 3.13 2.3 0.582 0.42 0.06–3.14
B*40 14.3 6.25 2.3 0.240 0.40 0.09–1.73
B*46 7.14 3.13 2.3 0.582 0.42 0.06–3.14
B*48 3.57 1.56 2.3 0.518 0.43 0.03–7.11
Chinese
(n=14)
B*15 21.43 7.81 2.7 0.084 0.31 0.09–1.12
B*18 3.57 1.56 2.3 0.518 0.43 0.03–7.11
B*48 3.57 0 3.6 0.304 NA NA
B*78 3.57 0 3.6 0.304 NA NA
Indian (n=13)
A*68 15.38 6.45 2.4 0.658 0.38 0.09–1.65
B*51 23.08 8.06 2.9 0.076 0.29 0.08–1.06
B*56 7.69 3.23 2.4 0.578 0.40 0.05–3.00
B*78 3.85 0 3.9 0.295 NA NA
Total Patients
(n=41)
A*30 2.43 0.53 4.6 0.217 0.21 0.02–2.37
A*68 4.88 2.11 2.3 0.248 0.42 0.10–1.72
B*48 2.44 0.53 4.6 0.217 0.21 0.02–2.37
B*78 2.44 0 2.4 0.09 NA NA
n=number of patients; P=p value derived from fisher exact test; OR=Odds
Ratio; CI=confidence interval; PT=patients; CTRL=controls; AF=allele
frequency in percentage; Number in bold indicate nearing significant p value; In
Pearson chi-square analysis, where a value in a 262 table was 0, the OR and
95% CI could not be calculated (NA, not available).
doi:10.1371/journal.pone.0013029.t003
HLA and Dengue
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e13029For the HLA-B allele group (Table 5 and 6), distinctively in the
Malay patients, decreased frequencies of alleles HLA-B*18 (12.5
fold decrease, P=0.101 in DF; 12.5 fold decrease, P=0.024,
Pc=0.576 in DHF), B*35 (4.4 fold decrease, P=0.163, OR=5,
95% CI=0.61–41.1 in DF; 2.9 fold decrease, P=0.202,
0R=3.33, 95% CI=0.69–16.11 in DHF) and B*39 (3.1 fold
decrease, P=1 in DF; 3.1 fold decrease, P=0.528 in DHF) were
observed both in DF and DHF patients. In addition, HLA-B*37
(3.1 fold decrease, P=0.528 in DHF), B*40 and B*58 (2.4 fold
decrease, P=0.648, 0R=2.47, 95% CI=0.27–22.92 in DHF)
alleles were decreased in frequencies in DHF patients only in this
population group. In the Chinese population, absence of HLA-
B*13 (9.4 fold decrease, P=0.174), B*39(3.1 fold decrease,
P=0.551) and decreased frequencies of HLA-B*58 (2.3 fold
decrease, P=0.327, 0R=2.46, 95% CI=0.50–12.10) alleles were
detected in DHF patients compared in study controls. Further,
HLA-B*44 (3.1 fold decrease, P=1 in DF, 3.1 fold decrease,
P=0.551 in DHF) allele was observed to be decreased in both
dengue case groups. Among the Indian DF patients, HLA-B*52
(2.1 fold decrease, P=0.665, 0R=2.19, 95% CI=0.24–19.75)
allele was noted to be decreased in frequency. Lower levels of the
HLA-B*15 (2.3 fold decrease, P=0.322, 0R=2.55, 95%
CI=0.52–12.57), B*51 (2.6 fold decrease, P=0.66, 0R=2.72,
95% CI=0.30–24.33), B*56 (3.2 fold decrease, P=0.55) and B*58
(3.2 fold decrease, P=0.546) alleles were also detected in DHF
patients in this group as compared to healthy donors.
Taking all the ethnic groups as a whole, lower levels of HLA-
B*35 (2.5 fold decrease, P=0.078, 0R=2.69, 95% CI=0.90–
8.03) allele was noted in DF patients while two other alleles (HLA-
B*18 : 5.3 fold decrease, P=0.017, Pc=0.408 and B*58 : 2.68 fold
decrease, P=0.126, 0R=2.83, 95% CI=0.80–10.01) were noted
to decrease in DHF patients as compared to controls.
HLA-A24: An association with dengue viral infection
HLA-A*24 is an allele very frequently expressed especially in
the DHF and DSS patients [29]. In this study, higher frequencies
of HLA-A*24 was found to be present largely in healthy and
DENV infected individuals in the Malay and Indian population
groups. As stated earlier, in the Chinese population, the presence
of this allele was noted to be higher in the DHF patients as
compared to healthy controls. We then subtyped the HLA-A*24
alleles in order to identify underlying associations of this allele to
dengue disease in this population. There is evidence that subtypes
may be negatively or positively associated with dengue disease
Table 4. Positive associations of HLA alleles in DHF patients in different races.
Alleles AF% AF% Fold P-value Pc-value OR 95% CI
(PT) (CTRL)
Malay (n=19)
A*26 2.63 0 2.6 0.373 NA NA
A*68 2.63 0 2.6 0.373 NA NA
B*13 15.79 3.13 5.1 0.049* 1.176 0.18 0.03–0.90
B*38 13.16 6.25 2.1 0.287 0.44 0.11–1.75
B*48 5.26 1.56 3.4 0.554 0.29 0.03–3.26
B*53 2.63 0 2.6 0.373 NA NA
B*54 2.63 0 2.6 0.373 NA NA
Chinese (n=16)
A*24 18.75 9.38 2.0 0.206 0.45 0.13–1.52
A*32 3.13 0 3.1 0.333 NA NA
B*07 3.13 1.56 2.0 1 0.49 0.03–8.13
B*14 3.13 1.56 2.0 1 0.49 0.03–8.13
B*27 6.25 1.56 4.0 0.257 0.24 0.02–2.73
B*37 6.25 0 6.3 0.109 NA NA
B*48 3.13 0 3.1 0.333 NA NA
B*52 3.13 0 3.1 0.333 NA NA
B*53 6.25 0 6.3 0.109 NA NA
B*56 6.25 0 6.3 0.109 NA NA
Indian (n=16)
A*30 6.25 0 6.3 0.113 NA NA
A*31 6.25 1.61 3.9 0.266 0.25 0.02–2.82
Total Patients (n=51)
A*30 2.94 0.53 5.5 0.124 0.18 0.02–1.70
B*48 2.94 0.53 5.5 0.124 0.18 0.02–1.70
B*53 2.94 0 2.9 0.042* 1.008 NA NA
n=number of patients; P=p value derived from fisher exact test; Pc=corrected P value; OR=Odds Ratio; CI=confidence interval; PT=patients; CTRL=controls;
AF=allele frequency in percentage; Number in bold (*) indicate significant P value; In Pearson chi-square analysis, where a value in a 262 table was 0, the OR and 95% CI
could not be calculated (NA, not available).
doi:10.1371/journal.pone.0013029.t004
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A*2401, A*2402, A*2407 and A*2410 were identified (Table 7).
Interestingly we found, the presence of HLA-A*2401 and HLA-
A*2410 allele frequencies were lower by 7.3 and 2.5 fold
respectively in all dengue case patients compared to healthy
individuals. However, the frequency level of HLA-A*2402 allele
was noted to be increased but only at 1.17 fold in the patients
compared to controls.
Discussion
Malaysia has a warm humid climate and a dense population in
urban areas. Both rural and urban Malaysian populations are
seasonally at risk of DENV infection [14]. The different ethnic
groups make this country rich in genetic diversity. HLA
classification with its extensive polymorphism is an excellent
marker for population genetic analysis and disease association
studies [30]. This is the first study on HLA determinants of
susceptibility and/or protection to DENV infection in a Malaysian
population.
The results obtained, reveal that, HLA-A*30 occurred more
frequently among the overall Malaysian DHF population group.
However, when we cluster our population into the different racial
groups, positive associations were noted with this allele and HLA-
A*31 only in the Indian DHF patients. Among the Malay DHF
patients, positive association were seen with HLA-A*26 and A*68
alleles while in the Chinese DHF patients, positive associations
were noted with HLA-A*24 and A*32 alleles. Although, we
observed positive associations, they were not statistically signifi-
cant. However with an AF of .2 fold rise in DHF patients as
compared to the healthy controls, this may suggest a probable risk
association to DENV infections. It has been shown that HLA-
A*24 was significantly associated with dengue disease severity in
Vietnamese population [31]. Others, have also recently demon-
strated that the subtype HLA-A*2402 was found significantly
higher in the DHF and DSS patients [29]. This further supports
our findings, where higher expression of HLA-A*2402 was seen in
our patients than in controls which implies a probable risk
association with severe disease in the Malaysian population too.
However, the obtained P value here was not significant and this
could probably be due to the lower number of samples. Risk
associations of HLA-A*30 and A*68 alleles have been reported for
Human Immunodeficiency Virus (HIV-Type 1) in Southern
Africans [32]. In Japanese HIV-1 disease patients, HLA-A*26
allele has been significantly associated with a slow progression to
AIDS [33] while HLA-A*31 allele has been linked with epithelial
cancer patients in Japan [34].
In the present study protective association of allele HLA-A*03
was observed for the first time in DHF patients in the pooled
ethnic population. When stratified by race, a stronger negative
association trend was identified especially in the Malay patient
group as compared to Chinese and Indian DHF patients.
Currently no association of this allele has been demonstrated by
others in dengue diseases, yet this allele has been shown to play an
essential role in elimination of Hepatitis B Virus (HBV) and
Hepatitis C Virus (HCV) respectively in the Caucasian and Irish
populations [35,36]. Also it has been reported that those carrying
the HLA-A*03 allele are negatively associated with Posttransplant
lymphoproliferative disease (PTLD) [37]. In the Chinese popula-
tion, the HLA-A*01 was found to be negatively associated with
DHF. Our finding is in contrast to that of the Cuban study where
this allele was shown to be positively associated with susceptibility
to DHF [20]. Other studies have suggested the increased
frequency of this allele in patients with primary dengue infection
[19] and its probable association in the development of severe
clinical disease [20]. Interestingly, within our population study
group, a probable reverse association (protective to susceptible) of
HLA-A*31 allele is seen between Chinese and Indian DHF
patients and HLA-A*68 allele between Indian and Malay DHF
patients. The role of HLA-A*68 in facilitating the rapid
progression of pleural disease and to allow the replication of
mycobacteria has been documented in HIV-positive patients [38].
Analysis of the HLA-B alleles in different ethnic groups suggests
a possible significant association of allele B*13 with disease
susceptibility, in the Malay DHF population. However, this result
is probably in contrast to the result obtained with Chinese DHF
population in this present study and previous study in Thai
populations, where allele B*13 was associated with protection to
dengue viral infections [39]. The varying frequencies of these
alleles in different populations may account, to some extent, for
increased resistance and/or susceptibility to diseases in different
populations.
The higher frequency of alleles B*38, B*48, B*53, B*54 and
complete absence or lower frequencies of alleles B*37, B*39, B*35,
B*40, B*58 in Malay DHF patients, as compared with controls,
were not definitively associated with susceptibility or protection to
dengue disease, as obtained P and Pc-values were not significant.
However, interestingly we noticed a significant decrease of allele
B*18 in the Malay DHF patients compared to control group. This
may suggest the probable protective role of this allele towards
DHF patients in this population. However, others have docu-
mented the risk association of HLA-B*18 in Malay patients with
nasopharyngeal carcinoma [40]. Furthermore, a probable protec-
tive association of HLA-B*18 allele have been reported in breast
feeding infants against HIV-1 acquisition [41]. Besides, two
different studies have shown, the association of HLA-B*54 allele
with a greater risk of developing myelopathy caused by type 1
human T-cell lymphotropic virus (HTLV-1) [42,43].
In the Chinese DHF patients, the presence of alleles HLA-B*07,
B*14, B*27, B*37, B*48, B*52, B*53, B*56 at the higher
frequencies and HLA-B*39, B*44, B*58 at the lower frequencies
Table 5. Negative associations of HLA alleles in DF patients in
different races.
Alleles AF% AF% Fold P-value OR 95% CI
(PT) (CTRL)
Malay (n=14)
B*18 0 12.5 12.5 0.101 NA NA
B*35 3.57 15.63 4.4 0.163 5 0.61–41.1
B*39 0 3.13 3.1 1 NA NA
Chinese (n=14)
B*44 0 3.13 3.1 1 NA NA
Indian (n=13)
A*02 7.69 19.35 2.5 0.216 2.89 0.60–13.9
B*52 3.85 8.06 2.1 0.665 2.19 0.24–19.75
Total Patients
(n=41)
B*35 4.88 12.11 2.5 0.078 2.69 0.90–8.03
n=number of patients; P=p value derived from fisher exact test; OR=Odds
Ratio; CI=confidence interval; PT=patients; CTRL=controls; AF=allele
frequency in percentage; Number in bold indicate nearing significant P value; In
Pearson chi-square analysis, where a value in a 262 table was 0, the OR and
95% CI could not be calculated (NA, not available).
doi:10.1371/journal.pone.0013029.t005
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not significant. However, others have reported the significant role of
these alleles in their study. For an example, the allele B*07, was
found to be lowin mainland SoutheastAsians[44] and a studydone
on Thais showed that T cell responses to an HLA-B*07-restricted
epitope on the dengue NS3 antigens correlate with disease severity
[45]. In addition, the HLA-B*14 and B*52 alleles were reported to
beprotective against denguediseaserespectivelyinCubanand Thai
populations [20,39], which are probably in contrast to our present
finding. The HLA-B*44 was on the other hand reported to be
protective against dengue disease in the Thais [39]. Recently, HLA-
B*27 was documented to have a protective association against
infectious agents such as HIV and HCV [46–48].
Lower allele frequencies of alleles B*15, B*51, B*56, B*58 in the
Indian DHF patients as compared with ethnically matched
controls, remain undefined as well, as obtained P-values were
also not significant. A study in ethnic Thais confirmed the
association of allele B*51, with clinical outcome, in previously
dengue exposed and immunologically primed individuals [39].
The involvement of HLA-B*51-restricted CTL responses to a
variety of viruses have been reported, including for Hantaan virus
which also causes a hemorrhagic fever [49]. However, the
variation in our results on allele B*51 which may suggest probable
Table 7. Allele Frequencies of HLA-A*24 subtypes in DENV
infected patients and healthy individuals.
Healthy Donor Patients (DF+DHF)
HLA-A*24 n=41 AF (%) n=20 AF (%)
2401 3 7.3 0 0
2402 21 51.2 12 60
2407 16 39 8 40
2410 1 2.5 0 0
n=number of patients; HLA=human leukocyte antigen; AF=allele frequency
(as percentage); DF=dengue fever; DHF=dengue hemorrhagic fever.
doi:10.1371/journal.pone.0013029.t007
Table 6. Negative associations of HLA alleles in DHF patients in different races.
Alleles AF% AF% Fold P-value Pc-value OR 95% CI
(PT) (CTRL)
Malay (n=19)
A*03 0 9.38 9.4 0.082 NA NA
B*18 0 12.5 12.5 0.024* 0.576 NA NA
B*35 5.26 15.63 2.9 0.202 3.33 0.69–16.11
B*37 0 3.13 3.1 0.528 NA NA
B*39 0 3.13 3.1 0.528 NA NA
B*40 2.63 6.25 2.4 0.648 2.47 0.27–22.92
B*58 2.63 6.25 2.4 0.648 2.47 0.27–22.92
Chinese (n=16)
A*03 0 6.25 6.3 0.298 NA NA
A*01 0 3.13 3.1 0.551 NA NA
A*31 0 3.13 3.1 0.551 NA NA
B*13 0 9.38 9.4 0.174 NA NA
B*39 0 3.13 3.1 0.551 NA NA
B*44 0 3.13 3.1 0.551 NA NA
B*58 6.25 14.06 2.3 0.327 2.46 0.50–12.10
Indian (n=16)
A*03 6.25 12.9 2.1 0.486 2.22 0.44–11.15
A*33 0 4.84 4.8 0.549 NA NA
A*68 3.13 6.45 2.1 0.658 2.14 0.23–19.97
B*15 6.25 14.52 2.3 0.322 2.55 0.52–12.57
B*51 3.13 8.06 2.6 0.66 2.72 0.30–24.33
B*56 0 3.23 3.2 0.55 NA NA
B*58 0 3.23 3.2 0.546 NA NA
Total Patients (n=51)
A*03 1.96 9.47 4.8 0.015* 0.18 5.23 1.19–23.02
B*18 0 5.26 5.3 0.017* 0.408 NA NA
B*58 3.26 7.89 2.7 0.126 2.83 0.80–10.01
n=number of patients; P=p value derived from fisher exact test; Pc=corrected P value; OR=Odds Ratio; CI=confidence interval; PT=patients; CTRL=controls;
AF=allele frequency in percentage; Number in bold indicate (*) significant P value; Number in bold indicate nearing significant P value In Pearson chi-square analysis,
where a value in a 262 table was 0, the OR and 95% CI could not be calculated (NA, not available).
doi:10.1371/journal.pone.0013029.t006
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other populations could be due to their distinctly diverse genetic
background.
In this study the P value just reached significant levels for HLA-
A*03, B*13 and B*18 before Bonferoni correction. Nevertheless, it
is essential to verify that the loss of significance might probably be
as a consequence, exclusively of the rigor of statistical analysis, as
the P-values without correction were obtained to be significant. An
independent study with a larger number of patient samples may
probably resolve this issue.
Previous cohort studies by others have reported that, DF and
DHF patients show significant diversity in allele frequency to each
other or to control, signifying that DF and DHF involve
genetically distinct immune response. This support our findings
too, where in the DF group specifically, the alleles HLA-A*68 and
HLA-B*78 were increased in frequencies (nearing significant;
P=0.09). In the Malay population, the presence of HLA-A*30,
B*37, B*40 and B*46 were noticed more than two fold rise in DF
patients compared to healthy individuals. In Chinese DF patients,
increased in HLA-B*15 (nearing significant; P=0.084), B*18 and
B*78 and in the Indian DF patients increased in HLA-A*68, B*51
(nearing significant; P=0.076), B*56 and B*78 were seen
compared to controls respectively. In the negative association of
HLA alleles in DF patients, the allele frequency of HLA-
B*35(nearing significant; P=0.078) was seen to be decreased in
overall population and specifically HLA-A*02 and B*52 in Indian
DF patients. A recent study have documented the negative
association of HLA-B*35 in Mexican Mestizo patients with DF.
Though the presence of these alleles does not differ significantly in
DF patients compared to control, yet, interestingly as mentioned
earlier we do also notice the expression of different allele with the
same trend of allele frequencies in our DF and DHF group [50].
The HLA-mediated restriction of the T cell response to dengue
viruses has been repeatedly documented to promote different
infection outcomes. The correlation of HLA-A*03 with CD8 T
cell responses has been determined in our previous study [51]. Five
peptides presented by HLA-A*03 was found to be negatively
associated with dengue disease. These 5 peptides (1 peptide from
NS2B protein, 2 peptides from NS3 protein and 1 peptide from
NS4B and NS5 proteins) belong to the non-structural region of the
DENV and were associated with secondary DENV-1 infections.
One of the peptides RVIDPRRCMK422–431 from NS3 region of
the DENV-2 was recognized by patients from different ethnics
(Malay, Chinese and Indian) in our population possessing different
type of HLA alleles. This could probably be the immunodominant
peptide as it possesses the highest T cell responses in comparison
with the other four recognized peptides.
In conclusion, the genetic variations among our study
population have expanded our knowledge of the alleles that
contribute to risk and/or protection of dengue viral infection in
the three ethnic groups in Malaysia. Further studies are definitely
required to assess these potential associations in a larger
population group and to understand whether these associations
result from individual genotype or the haplotypes. Notably, the
genetic documentations, in support with previous reports by
others, with specific associations of HLA molecules with dengue
disease will be an essential tool in identifying the dengue specific
epitopes presented by susceptible and/or protective alleles. This
fundamental data also contributes in further understanding
dengue immunopathogenesis and relevance for DENV vaccine
design in our population.
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